Skip to main content
SpringerLink
Log in

Haloperidol as a first-line delirium treatment “will not contribute to the establishment of drug therapy for delirium based on risk-benefit assessment”

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Miyaji S, Yamamoto K, Hoshino S, Yamamoto H, Sakai Y, Miyaoka H.Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients. Psychiatry and Clinical Neurosciences 61: 275-282, No. 3, Jun 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haloperidol as a first-line delirium treatment “will not contribute to the establishment of drug therapy for delirium based on risk-benefit assessment”. React. Wkly. 1156, 5 (2007). https://doi.org/10.2165/00128415-200711560-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711560-00015

Keywords

Search

Navigation